Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease:A Systematic Review of Cost-Effectiveness by Marquina, Clara et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease
A Systematic Review of Cost-Effectiveness
Marquina, Clara; Zomer, Ella; Vargas-Torres, Sandra; Zoungas, Sophia; Ofori-Asenso,
Richard; Liew, Danny; Ademi, Zanfina
Published in:
PharmacoEconomics
DOI:
10.1007/s40273-020-00936-0
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020). Novel
Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-
Effectiveness. PharmacoEconomics. https://doi.org/10.1007/s40273-020-00936-0
Download date: 10. sep.. 2020
Vol.:(0123456789)
PharmacoEconomics 
https://doi.org/10.1007/s40273-020-00936-0
SYSTEMATIC REVIEW
Novel Treatment Strategies for Secondary Prevention 
of Cardiovascular Disease: A Systematic Review of Cost‑Effectiveness
Clara Marquina1  · Ella Zomer1  · Sandra Vargas‑Torres1  · Sophia Zoungas1  · Richard Ofori‑Asenso1,2  · 
Danny Liew1  · Zanfina Ademi1 
 
© Springer Nature Switzerland AG 2020
Abstract
Background New pharmacological therapies for the treatment of cardiovascular disease (CVD) have emerged in recent 
years. The high rates of CVD and the need for long-term treatment to decrease risk factors makes cost-effectiveness crucial 
for their successful long-term implementation.
Objective This study assessed cost-effectiveness studies of novel pharmacological treatments (ezetimibe, proprotein con-
vertase subtilisin/kexin type 9 [PCSK9] inhibitors, omega-3 polyunsaturated fatty acids [n-3 PUFAs], and the cardiovascular 
polypill) compared with standard care for the secondary prevention of CVD.
Methods We searched seven databases and the reference list of selected literature reviews for eligible cost-effective analyses 
(CEA) published between January 2009 and January 2020 that evaluated the above novel treatments versus standard care. 
Two independent reviewers performed the screening and evaluation in accordance with the Consolidated Health Economic 
Evaluation Reporting Standards statement. Cost results were adapted to 2018 US dollars (US$) to facilitate comparisons 
between studies. Consideration of cost-effectiveness was based on the original study criteria.
Results Thirty-two studies were included in this review, most of them adopting a healthcare perspective. Studies evaluating 
ezetimibe, PCSK9 inhibitors and n-3 PUFAs assessed their addition to standard care compared with standard care alone, 
while studies analysing the polypill evaluated the replacement of multiple monotherapies for a fixed-dose combination. Ten 
studies reported on ezetimibe, fifteen evaluated PCSK9 inhibitors, five focused on n-3 PUFAs and seven on the polypill. From 
a healthcare perspective, ezetimibe was cost effective in 62.5% of the studies (incremental cost-effectiveness ratios [ICERs] 
ranged from US$27,195 to US$204,140), n-3 PUFAs in 60% (ICERs from US$57,128 to US$139,082) and the cardiovascular 
polypill in 100% (ICERs from dominant to US$30,731) compared with standard care. Conversely, only 10% of the studies 
considered PCSK9 inhibitors cost effective compared with standard care from a healthcare perspective (ICERs ranged from 
US$231,119 to US$1,223,831). Additionally, ezetimibe was cost effective in 50% of the studies, PCSK9 inhibitors in 33% 
and the polypill in 50% of the studies adopting a societal perspective. The key model-related parameters predicting cost-
effectiveness included drug cost, time horizon, and the baseline risk of cardiovascular events.
Conclusions Based on current pricing and willingness-to-pay thresholds, most CEA studies considered ezetimibe, n-3 PUFAs 
and the polypill to be cost effective compared with standard care but not PCSK9 inhibitors for secondary prevention of CVD.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-020-00936 -0) contains 
supplementary material, which is available to authorized users.
 * Zanfina Ademi 
 zanfina.ademi@monash.edu
1 School of Public Health and Preventive Medicine, Monash 
University, 553 St Kilda Rd, Melbourne, VIC 3004, 
Australia
2 Department of Pharmacy, Faculty of Health and Medical 
Sciences, University of Copenhagen, Copenhagen, Denmark
1 Introduction
Although rates of cardiovascular disease (CVD) have 
decreased over the last 30 years, it remains the leading cause 
of mortality worldwide, accounting for more than 30% of all 
global deaths in 2017 [1]. People with established CVD are 
at higher risk of experiencing life-threatening cardiovascular 
events, and their quality of life is significantly reduced [2]. 
Moreover, due to the high prevalence of CVD and the high 
costs associated with its management, understanding of the 
cost-effectiveness of treatments is crucial to inform decision 
making about healthcare spending.
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Key Points for Decision Makers 
Ezetimibe, proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors, omega-3 polyunsaturated fatty acids 
(n-3 PUFAs), and the cardiovascular polypill can reduce 
the residual cardiovascular risk in statin-treated patients 
with established CVD. However, their cost-effectiveness 
remains unclear.
This systematic review found that in most CEAs, the 
addition of ezetimibe and n-3 PUFAs to statin therapy 
was found to be good value for money, when adopting a 
healthcare system perspective. The cardiovascular polyp-
ill was also cost effective in all the studies, suggesting it 
as a solid option for the secondary prevention of CVD. 
Conversely, most studies found PCSK9 inhibitors to be 
not cost effective. These overall results were consistent 
after adaptation to a US setting.
The decision models were most influenced by the time 
horizon projected, the baseline cardiovascular risk, and 
the cost of the drugs.
randomised controlled trials (RCTs) [7], but their cost-effec-
tiveness has been widely debated [8, 9]. Ezetimibe reduces 
intestinal absorption of cholesterol by blocking the inter-
nalisation of the cholesterol transport protein Niemann–Pick 
C1-like 1 (NPC1L1) to the enterocytes [10]. Several RCTs 
analysing ezetimibe versus statins have shown a reduction 
in cardiovascular events [11], but cost-effectiveness results 
have been inconsistent [12, 13].
Mixed dyslipidaemia, including hypertriglyceridaemia, is 
also associated with a higher risk of CVD even after adjust-
ing for LDL-C levels [14–16]. Omega-3 polyunsaturated 
fatty acids (n-3 PUFAs) have been shown to reduce plasma 
levels of triglycerides by downregulating very-low-density 
lipoprotein production and increasing β-oxidation of fatty 
acids in different tissues [16]. Several RCTs have shown 
n-3 PUFAs to be effective at reducing the risk of CVD [17, 
18], and its cost-effectiveness has been analysed in several 
studies.
The complexity of these disorders usually requires peo-
ple with established CVD, or at high risk, to take multiple 
medications, which tends to decrease adherence [19]. The 
cardiovascular polypill, consisting of three or four active 
ingredients in a fixed-dose combination, has been shown to 
increase adherence, which has a direct impact on subsequent 
cardiovascular events [20, 21]. Several studies have analysed 
the cost-effectiveness of the polypill for secondary preven-
tion in different settings [22].
In the present study, we systematically reviewed recent 
literature on the cost-effectiveness of novel treatment strat-
egies (ezetimibe, PCSK9 inhibitors, n-3 PUFAs and the 
cardiovascular polypill) for secondary prevention of CVD, 
adapted the results to a common cost-effectiveness plane and 
identified the factors driving their cost-effectiveness.
2  Methods
The present study was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) reporting guidelines [23] and the qual-
ity of reporting was assessed using the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) state-
ment [24]. The PRISMA checklist is available in Appendix 1 
(see Electronic Supplementary Material [ESM]). The study 
protocol was pre-registered in PROSPERO (ID 152196).
2.1  Eligibility Criteria for Study Selection
Studies were selected based on the following criteria: the tar-
get population were adults (age ≥ 18 years) with established 
CVD (atherosclerotic disease or any previous acute cardio-
vascular event), with no restrictions set for co-morbidities 
or co-treatment strategies. Studies that reported results for 
CVD encompasses multifactorial disorders with well 
described modifiable risk factors including high blood pres-
sure, smoking, and dyslipidaemia [2]. High plasma levels of 
low density lipoprotein cholesterol (LDL-C) is considered 
one of the most important modifiable risk factors for CVD 
[2], and recent meta-analyses undertaken by the Cholesterol 
Treatment Trialists’ (CTT) Collaboration of statin trials on 
primary and secondary prevention populations revealed 
that a 1-mmol/L reduction in plasma LDL-C was associ-
ated with a 10% reduction in all-cause mortality (relative 
risk [RR] 0.90, 95% confidence interval [CI] 0.87–0.93) and 
a 24% reduction in major coronary events (RR 0.76, 95% CI 
0.73–0.79) [3, 4]. Despite the success of statins in decreas-
ing plasma cholesterol levels, many patients, especially those 
with established CVD, are unable to reach desirable LDL-C 
targets even with the maximum doses of statins [5], and 
there is a significant on-treatment residual risk, with 5-year 
major cardiovascular event rates of 22% among secondary 
prevention patients [3]. Hence, there is a significant interest 
in additive therapies to minimise this residual risk. In recent 
years, two novel agents—proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors and ezetimibe—have been 
included as second-line treatments. PCSK9 inhibitors are 
human monoclonal antibodies that bind human PCSK9-
reducing plasma LDL-C concentrations by decreasing the 
degradation rates of the LDL-C hepatocyte receptor [6]. The 
effectiveness of PCSK9 inhibitors at lowering the risk of 
non-fatal cardiovascular events has been shown in several 
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mixed populations (i.e. including patients with high risk but 
no established CVD) were excluded. The focus of the analy-
sis was on novel lipid-lowering strategies and the cardiovas-
cular polypill. We considered novel lipid-lowering strategies 
as those developed and approved after statins, including n-3 
PUFAs, ezetimibe and PCSK9 inhibitors. The cardiovas-
cular polypill was defined as a fixed-dose combination of 
three or four components: aspirin, an angiotensin convert-
ing enzyme (ACE) inhibitor, a statin and in some cases an 
anticoagulant. We did not set any restrictions on the defini-
tion of ‘standard therapy’; rather, this was as defined by 
the individual studies. The main outcome of interest was 
the incremental cost-effectiveness ratio (ICER) in terms 
of net costs divided by net benefits. Benefits were reported 
as quality-adjusted life-years (QALYs), disability-adjusted 
life-years (DALYs) averted or cardiovascular events averted. 
We included cost-effectiveness studies published in peer-
reviewed journals, comprising a full economic evaluation 
involving any type of decision model that reported an ICER. 
We excluded within-trial cost effective studies with the aim 
to capture long-term cost-effectiveness and budget impact 
studies and value-based price valuations.
2.2  Search Strategy
Two reviewers (CM, ZA) developed the search strategy 
using Medical Subject Heading (MeSH) terms based on the 
concepts of CVD, economic evaluation and the interventions 
of interest (n-3 PUFAs, ezetimibe, PCSK9 inhibitors and the 
polypill). The literature search was conducted in MEDLINE 
via Ovid, EMBASE via Ovid, Scopus, the Cochrane Library, 
the Economic Literature Database (EconLit) via EBSCO-
Host, the NHS Economic Evaluation Database (EED), and 
the Database of Abstracts of Reviews of Effects (DARE). We 
searched for studies published between January 2009 and 31 
January 2020 (full search strategies are available in Appen-
dix 2, see ESM). No language restrictions were applied. 
Limiting the search period to the past 10 years reflected the 
focus on novel treatments. The reference lists of included 
studies and previous reviews of interest were also screened 
for additional studies. One reviewer (CM) screened titles 
and abstracts, and two reviewers screened the full text of 
selected studies (CM, SV). Disagreements about the inclu-
sion of studies were resolved by consultation with a third 
reviewer (ZA). Conference abstracts and reports not pub-
lished in peer-reviewed journals were excluded.
2.3  Data Extraction and Synthesis
Data extraction was performed using a data extraction tem-
plate adapted for the outcomes of interest. Collected data 
included author, year, country of setting, objective of the 
study, general characterisation of the model (model type, 
perspective, time horizon, treatment arms, discount rate and 
currency year), baseline risks and treatment effectiveness 
and their sources, types of costs included, total costs, total 
outcomes, ICERs and results from sensitivity analyses. Stud-
ies were grouped by treatment strategies in data extraction 
summaries. Treatments were defined as cost effective based 
on the author’s conclusion.
2.4  Quality Assessment
Reporting quality was assessed independently by two 
reviewers (CM and SV) using the 24-item checklist provided 
in the CHEERS statement. Each item was scored with 0, 
0.25, 0.5, 0.75 or 1 point based on criteria. After grading 
the studies, both reviewers (CM, SV) shared their results and 
the final CHEERS grade was obtained as an average of both 
evaluations. In addition, the results for each CHEERS item 
were summarised in a colour histogram with ‘yes’, ‘no’ and 
‘unclear’ categories, depending on the criteria fulfilment. 
Information regarding funding sources was also collected 
and reported in the results.
2.5  Cost Adjustments Methods
To be able to compare ICERs in a common currency and 
cost-effectiveness plane, all costs were adapted to 2018 US 
dollars (US$) using the cost-adjustment method described 
by Ademi et al. [25]. Briefly, reported costs were adjusted 
for the level of healthcare resource utilisation, the prices 
of healthcare in each country and finally adjusted for US 
inflation. Further details for the cost adaptation process can 
be found in Appendix 3 (see ESM). Studies that did not 
report the cost year [26–30] were excluded for adaptation. 
Authors from studies not reporting cost year were contacted 
by e-mail in an effort to complete the missing data. In addi-
tion, results from Permpanich et al. [31] and Yang et al. [32] 
could not be adapted due to the lack of data on purchas-
ing power parities. Korman and Wisloff [33] reported cost 
results in Euros but the study was based in Norway, and Lin 
et al. [34] reported costs in international dollars but the study 
was set in five low- and medium-income countries (LMIC), 
and both studies were excluded from cost adjustment. Addi-
tionally, results from studies that reported costs in 2018 US$ 
were not adapted and the original results were used.
3  Results
3.1  Search Results
The literature search yielded 5923 unique records after 
duplicate removal. After screening the titles, 700 studies 
were selected for abstract screening, of which 142 studies 
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were selected for full-text screening. Only 35 studies were 
included for data extraction and quality assessment. Four 
studies were excluded due to their not reporting ICERs as 
an outcome of interest, one was excluded due to being a 
within-trial analysis, and two studies were included after 
review of the references of the selected studies. In total, 32 
studies were included in this systematic review. The search-
ing, screening and inclusion procedure is summarised in the 
PRISMA flowchart in Fig. 1.
3.2  Quality Appraisal
Results from the CHEERS assessment can be found in 
Appendix 4 (see ESM). Briefly, the overall average score 
was 0.75 points (out of a total of 1 point). Ezetimibe stud-
ies had the highest average score (0.85 points), followed by 
PCSK9 inhibitors (0.80 points), n-3 PUFAs (0.78 points) 
and studies analysing the polypill (0.74 points).
Overall, 16 out of the 32 included studies declared 
specific funding for the project, and from those, 10 stud-
ies declared industry support. Three out of 10 studies [13, 
35, 36] were funded by industry for ezetimibe (30%), five 
out of 15 [26, 29, 37–39] for PCSK9 inhibitors (33%), one 
out of five (20%) [40] for n-3 PUFAs, and one out of seven 
(14%) [41] for the polypill. Granular information on funding 
sources can be accessed in Appendix 5 (see ESM).
3.3  General Characteristics of the Included Studies
The general characteristics of the included articles organised 
by treatment strategies are summarised in Table 1. Of the 
selected studies, ten evaluated ezetimibe [12, 13, 32, 33, 
35, 36, 42–45], 15 PCSK9 inhibitors [12, 26, 28–30, 33, 
37–39, 43–48], five n-3 PUFAs [31, 40, 49–51], and seven 
the polypill [27, 34, 41, 52–55]. Four out of the 15 stud-
ies focusing on PCSK9 inhibitors also reported the ICERs 
of ezetimibe versus statins, but considering ezetimibe as 
a comparator [12, 33, 43, 44], and those results have also 
been included and reported in this review. Of note, the study 
by Dressel et al. [28] used ezetimibe as a comparator, but 
did not report the ICER for ezetimibe. Only five out of 32 
studies [31, 32, 34, 45, 53] were set in LMICs, and only 
seven [31, 32, 34, 45, 46, 49, 53] were based in non-Western 
countries. Most of the studies analysed lifetime horizons (28 
studies) [12, 13, 25–29, 31–40, 42–52, 55], and the majority 
used Markov models (29 studies) [12, 13, 26, 28–33, 35–52, 
54, 55]. QALYs were the preferred outcome to report health 
benefits (29 studies) [12, 13, 26–29, 31–33, 35–52, 54, 55].
3.3.1  Ezetimibe
Among the ten studies evaluating the cost-effectiveness of 
ezetimibe versus standard therapy, five were set in the US 
[12, 13, 42–44] and the rest in Finland [36], the UK [35], 
Fig. 1  PRISMA flow diagram. 
PRISMA Preferred Reporting 
Items for Systematic Reviews 
and Meta-Analyses
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Norway [33], Thailand [45] and China [32]. All the stud-
ies analysed the addition of ezetimibe 10 mg/day to statin 
therapy. Additionally, Korman and Wisloff [33] analysed 
ezetimibe alone versus no treatment for statin-intolerant 
patients. The mean age of the population ranged from 53 to 
67 years, and all studies with the exception of Kongpakwat-
tana et al. [45] and Almalki et al. [42] reported mean plasma 
LDL-C levels > 70 mg/dL, which reflects current guideline 
recommendations for the prescription of ezetimibe (i.e. 
patients with established CVD not meeting lipid targets).
All the included studies used Markov models with yearly 
cycles and lifetime horizons [12, 13, 32, 33, 35, 36, 42–45]. 
There was a variety of model structures, with studies mod-
elling between three [45] and 28 [13] health states. All the 
studies [12, 13, 32, 33, 35, 36, 42–45] included fatal and 
non-fatal coronary heart disease, and all studies but two [35, 
36] included fatal and non-fatal stroke. Three studies also 
modelled unstable angina [35, 36, 42] and Almalki et al. [42] 
also considered coronary revascularisation. Three studies 
[12, 43, 44] used the CVD Policy Model, a computer-sim-
ulation Markov model developed and validated for the US 
context that simulates the incidence, prevalence, mortality 
and costs of stroke and chronic heart failure in the whole 
population aged ≥ 35 years using age- and sex-specific data. 
Seven studies [12, 32, 33, 35, 42–44] analysed a healthcare 
system perspective, Soini et al. [36] adopted a societal per-
spective, Kongpakwattana et al. [45] analysed both health-
care system and societal perspectives, and Davies et al. [13] 
considered a US payer perspective. Costs and health ben-
efits were discounted with rates ranging between 3% and 
4%. All the studies [12, 13, 32, 33, 35, 36, 42–45] reported 
health benefits in terms of QALYs. Three studies [12, 43, 
44] modelled adverse events as penalties, and Yang et al. 
[32] included costs due to adverse events. Further details on 
the characteristics are provided in Appendix 6 (see ESM).
3.3.2  Proprotein Convertase Subtilisin/Kexin Type 9 
(PCSK9) Inhibitors
Among the 15 selected studies evaluating PCSK9 inhibi-
tors, three were updates from previous published models 
incorporating new clinical or pricing data [38, 44, 48], and 
the rest were original research articles. Eight studies were 
set in the US [12, 26, 29, 37, 38, 43, 44, 48], two in Spain 
[30, 39], and the rest in Japan [46], Norway [33], Australia 
[47], Germany [28] and Thailand [45]. The comparator was 
statins or statins plus ezetimibe. The mean age of the popula-
tion was > 60 years in all the included studies and baseline 
LDL-C levels ranged from 70 to 150 mg/dL.
All the studies used a Markov model with yearly cycles 
except Kumar et al. [47], who modelled 5-year cycles, and 
all used lifetime horizons with the exception of Olry de 
Labry Lima et al. [30], who used a 10-year time horizon Ta
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[30]. The model structure varied, with studies simulating 
from three [45] to eleven [39] health states, and important 
differences in the variety of the included cardiovascular 
events, with fatal and non-fatal myocardial infarction and 
fatal and non-fatal stroke modelled in 13 studies [12, 26, 
28, 33, 37–39, 43–48]. Three of the studies [12, 43, 44] 
used the CVD Policy Model. Two studies [37, 38] adopted 
a societal perspective, Kongpakwattana et al. [45] used both 
a healthcare system and a societal perspective, Arrieta et al. 
[48] a healthcare and a payer perspective, Gandra et al. [26] 
used a US payer perspective, and two studies [28, 29] did not 
report the perspective adopted for the analysis. The rest of 
the studies [12, 30, 33, 39, 43, 44, 46–48] adopted a health-
care system perspective. All the studies with the exception 
of Olry de Labry Lima et al. [30] applied annual discount 
rates to costs and benefits, ranging from 2 [46] to 5% [47]. 
Health benefits were mostly reported as QALYS, but Olry 
de Labry Lima et al. [30] reported averted cardiovascular 
events. Three studies [12, 43, 44], included adverse events 
derived from injection of PCSK9 inhibitors as a small pen-
alty in the utility values, but such penalty was not included 
in the costs or risk of events. Additional information on the 
characteristics of the models used are available in Appen-
dix 6 (see ESM).
3.3.3  Omega‑3 Polyunsaturated Fatty Acids (n‑3 PUFAs)
Five of the 32 included studies evaluated the cost-effec-
tiveness of n-3 PUFAs added to statin therapy. Two studies 
were set in Australia [50, 51], and the other three in the 
UK [40], Thailand [31] and Japan [49]. Two studies [31, 
40] analysed the addition of 1 g/day of highly purified n-3 
PUFAs, and one study [49] analysed the addition of 18 g/
day of eicosapentaenoic acid (EPA), which is a specific sub-
class of n-3 PUFA. The last two [50, 51] evaluated statins 
plus 4 g/day of icosapent ethyl, a highly purified and stable 
EPA ethyl ester. The average age of the modelled popula-
tions was > 60 years in the five studies [31, 40, 49–51]. Two 
studies [31, 49] specifically targeted patients with previous 
myocardial infarction, Cowie et al. [40] focused on patients 
with chronic heart failure, and the two studies set in Aus-
tralia specified patients with established CVD and hyper-
triglyceridaemia [50, 51].
All the studies [31, 40, 49–51] used a Markov model 
with yearly cycles and a lifetime horizon and the number 
of health states ranged between three [50] and six [40, 49]. 
Myocardial infarction and stroke, both fatal and non-fatal, 
were included in all the models [31, 40, 49–51]. Kodera 
et al. [49] also included stable angina, while Ademi et al. 
[50] also modelled coronary revascularisation and hospitali-
sations due to atrial fibrillation. All studies [31, 40, 49–51] 
adopted a healthcare system perspective, discounted costs 
and benefits, with annual discount rates between 2% [49] 
and 5% [50], and all [31, 40, 49–51] evaluated health out-
comes in terms of QALYs. Only Ademi et al. [50] modelled 
the health outcomes and costs of adverse events. Further 
information on the models can be accessed in Appendix 6 
(see ESM).
3.3.4  Polypill
Among the seven selected studies evaluating the polypill 
strategy, two were set in the US [27, 52], and the rest in 
India [53], the UK [41], Spain [54], Germany [55], and Lin 
et al. [34] analysed the polypill in five different LMICs. 
Three studies [41, 54, 55] analysed three-component polyp-
ills (aspirin, an ACE inhibitor and a moderate-potency sta-
tin), the other three [34, 52, 53] analysed a four-component 
polypill (aspirin, an ACE inhibitor, a beta-blocker and a 
moderate- or low-potency statin) and Gaziano et al. [27] ana-
lysed four-component polypills with three different statins 
of different potencies. All the studies used multiple mono-
therapies as a comparator. The populations modelled had a 
mean age of > 60 years in most of the studies [27, 41, 52, 54, 
55]. Five of the studies [41, 52–55] targeted patients with 
previous myocardial infarction, Lin et al. [34] considered 
patients with previous ischaemic heart disease or stroke, and 
Gaziano et al. [27] described patients with established CVD.
Four of the seven studies [41, 52–55] used a Markov 
model, Megiddo et al. [53] used a deterministic model, Lin 
et al. [34] used a micro-simulation model and Gaziano et al. 
[27] used the CVD PREDICT model. The CVD PREDICT 
is a micro-simulation model developed to predict the risk 
of cardiovascular events based on the Framingham risk 
equations, extrapolating risk profiles from US demographic 
trends and rates of medication [56]. The number of included 
health states varied between nine [27] and five [52], with 
six out of seven studies [27, 34, 41, 52, 54, 55] including 
myocardial infarction and stroke, both fatal and non-fatal. 
All the studies included CVD death. The time horizon of the 
analysis was lifetime for three studies [34, 52, 55], 10 years 
for two studies [41, 54], Gaziano et al. [27] evaluated both 
5 years and a lifetime horizon, and Megiddo et al. [53] did 
not report the time horizon. Four studies [34, 41, 54, 55] 
adopted a healthcare system perspective, Ito et al. [52] used 
a societal perspective, and Gaziano et al. [27] analysed both 
perspectives using different time horizons for each of them. 
The study by Megiddo et al. [53] did not report the per-
spective used in the analysis. All the studies [27, 34, 41, 
52–55] discounted cost and benefits using rates between 3 
and 3.5%. The outcomes of interest were mostly reported as 
QALYs [27, 41, 52, 54, 55], while Megiddo et al. [53] and 
Lin et al. [34] used DALYs averted. Only Lin et al. [34] and 
Gaziano et al. [27] included the impact of adverse events in 
the model. Further details on the model characteristics can 
be accessed in Appendix 6 (see ESM).
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3.4  Baseline Risks and Treatment Effects
3.4.1  Ezetimibe
Six out of ten studies profiled the model population after 
local registries and databases [12, 13, 33, 36, 43, 44], three 
studies [32, 35, 42] after the patient characteristics of clini-
cal trials, and Kongpakwattana et al. [45] used patient pro-
files from a meta-analysis of RCTs. To model baseline risks, 
four studies [12, 36, 43, 44] used local observational data, 
five studies [13, 32, 35, 42, 45] used baseline data from clini-
cal trials and meta-analyses, and Korman and Wisloff [33] 
used both observational and clinical data. Two studies [35, 
36] used the Framingham risk score and two studies [13, 33] 
applied risk reduction estimates from the CTT Collaboration 
meta-analyses. Eight out of the ten studies [12, 13, 33, 35, 
36, 43–45] applied age-related trends to baseline risk for 
fatal and non-fatal events.
Six studies [12, 13, 33, 35, 36, 44] used surrogate mark-
ers to model the treatment effect, estimating the relative 
reduction of cardiovascular risk from LDL-C changes 
reported from clinical trials and meta-analyses. As for 
baseline events, cardiovascular risk was modelled using the 
Framingham risk score or risk reduction values from CTT 
Collaboration meta-analyses. The other four studies [32, 
42, 43, 45] used event rates from clinical trials with car-
diovascular event endpoints to model the treatment effect. 
All the studies [12, 13, 32, 33, 35, 36, 42–45] modelled the 
intervention and the treatment effect to last for the duration 
of the model.
The most used clinical trial was the IMProved Reduc-
tion of Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT) trial, the largest RCT with hard outcomes 
to date that analysed ezetimibe + simvastatin versus simvas-
tatin. It included more than 18,000 patients with established 
CVD and showed a hazard ratio (HR) of 0.93 (95% con-
fidence interval [CI] 0.89–0.99) for ezetimibe/simvastatin 
versus simvastatin for a composite of fatal and non-fatal car-
diovascular events at 7 years’ follow-up [11]. Further details 
regarding model input sources are available in Appendix 7 
(see ESM).
3.4.2  PCSK9 Inhibitors
Eleven out of the 15 studies [12, 26, 28, 29, 33, 37–39, 43, 
44, 46] used observational data from registries and local 
databases to profile the model populations. Three studies 
[47, 48, 57] incorporated patient characteristics from the 
same clinical trial (FOURIER [Further Cardiovascular Out-
comes Research with PCSK9 Inhibition in Subjects with 
Elevated Risk] [7, 37]), and Kongpakwattana et al. [45] used 
data from a meta-analysis of RCTs. To estimate the baseline 
risk of cardiovascular events, twelve studies [12, 26, 28, 29, 
33, 37–39, 43, 44, 46, 48] used observational data from local 
registries and databases while the other three [33, 45, 47] 
used data from clinical trials. Eleven out of the 15 studies 
[12, 26, 29, 33, 37, 38, 43–45, 47, 48] applied age-related 
trends to the event rates in the model, for both fatal and 
non-fatal events.
Eight studies [12, 26, 29, 33, 37–39, 44] used clinical 
trials with surrogate markers to model the treatment effect, 
while four studies [43, 46, 47, 57] incorporated event rates 
from clinical trials with fatal and non-fatal cardiovascular 
events as endpoints, and Kongpakwattana et al. [45] used 
event rates from a meta-analysis of RCTs. In addition, Arri-
eta et al. [48] included both event rates from a clinical trial 
for the duration of the trial, and surrogate markers beyond 
the trial duration. Dressel et al. [28] modelled the treatment 
effect of PCSK9 inhibitors assuming relative risk reductions 
for cardiovascular events ranging from 10 to 50% compared 
with statin therapy. All the studies incorporated the inter-
vention and the treatment effect to last as long as the model 
time horizon.
Several different clinical trials and meta-analyses were 
used as sources for the treatment effects. The most used was 
the FOURIER trial, which was used in seven studies [30, 
37, 38, 44, 47–49]. The FOURIER trial was an RCT involv-
ing more than 27,000 patients analysing PCSK9 inhibitors, 
with a primary composite endpoint of non-fatal and fatal 
cardiovascular events. The results showed a reduction in the 
primary endpoint with an HR of 0.85 (95% CI 0.79–0.92) 
when compared with statin monotherapy [7]. More informa-
tion on model input sources can be accessed in Appendix 7 
(see ESM).
3.4.3  n‑3 PUFAs
Four out of the five included studies [40, 49–51] used data 
from clinical trials to profile the model populations, while 
Permpanich et al. [31] used data from a local registry. To 
model baseline risks, two studies [31, 40] used local demo-
graphic data and registries, while the other three studies 
[49–51] extracted baseline event rates from clinical trials. 
Only Ademi et al. [50] adjusted the event rates for increasing 
age, using local demographic data.
All the studies [31, 40, 49–51] used clinical trials with 
composites of cardiovascular events, or cardiovascular 
events plus all-cause mortality to model the treatment effect. 
Three of the five studies [31, 49, 50] modelled the interven-
tion effects for the duration of the model. The other two 
studies, Cowie et al. [40] and Gao et al. [51], modelled the 
intervention for a duration of 4 and 5 years, respectively. 
However, while Cowie et  al. [40] did not consider the 
treatment effect to extend beyond the intervention period, 
Gao et al. [51] assumed the health benefits to extend up to 
10 years.
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Only one trial was used as a treatment effect source in 
more than one study. The two most recent studies, Gao et al. 
[51] and Ademi et al. [50], used data from the Reduction of 
Cardiovascular Events with Icosapent Ethyl–Intervention 
(REDUCE-IT). The REDUCE-IT trial was an RCT includ-
ing 8179 patients, analysing the effectiveness of icosapent 
ethyl on cardiovascular event rates [18]. Results from the 
REDUCE-IT trial showed a 0.75 HR (95% CI 0.68–0.83) for 
the primary endpoint (a composite of fatal and non-fatal car-
diovascular events). More details about model input sources 
can be consulted in Appendix 7 (see ESM).
3.4.4  Polypill
Three studies [41, 54, 55] used assumptions from experts 
to model the characteristics of the study populations, while 
the other four studies used profiles from local demographic 
data [27, 34, 52, 53]. Baseline risks were estimated from 
local registries [27, 34, 41, 53, 55] or from the statin arm of 
clinical trials [52, 54] and two studies used the Framingham 
study to model cardiovascular risk [27, 53]. Two studies 
modelled an increase in cardiovascular risk with increasing 
age [27, 34].
Regarding the treatment effect, six studies [27, 34, 41, 52, 
54, 55] incorporated different adherence rates to both treat-
ment arms, with the polypill having higher compliance over 
a longer period. The remaining study did not model changes 
in adherence to treatment between the polypill and multiple 
monotherapies [53]. Five studies [27, 34, 41, 54, 55] used 
data from the UMPIRE (Use of a Multidrug Pill In Reducing 
cardiovascular Events) trial. The UMPIRE trial was an open-
label trial with a median follow-up of 15 months, including 
2004 participants with established CVD in India and Europe 
[21]. The results showed increased adherence, from 65% in 
multiple monotherapy users to 86% in polypill users, and 
parallel reductions in blood pressure levels and LDL-C lev-
els. Details regarding model input sources are available in 
Appendix 7 (see ESM).
3.5  Perspective and Costs
Granular information on included costs and perspective is 
provided in Appendix 8 (see ESM). The majority of the stud-
ies adopted a healthcare perspective, therefore the main costs 
captured were direct medical costs (hospitalisation, medica-
tion and outpatient appointments). Studies that included a 
societal perspective captured travelling, caregiver time and 
future consumption as additional costs. Only Gaziano et al. 
[27] reported the inclusion of productivity costs defined as 
labour market earnings lost.
Willingness-to-pay (WTP) thresholds were set according 
to different criteria. Five studies [31–33, 45, 50] used the 
criteria recommended by local health technology assessment 
(HTA) bodies, four studies [12, 27, 43, 44] used the criteria 
set by the American College of Cardiology/American Heart 
Association and four studies used the criteria set by WHO 
[26, 34, 37, 38]. Seven studies [39, 42, 46, 47, 49, 51, 52] 
cited other published sources, Toth et al. [29] used the rec-
ommendation of the Second Panel on Cost-effectiveness, 
and finally, 11 studies [13, 28, 35, 36, 40, 41, 48, 53–55, 57] 
did not report the source used to set the WTP threshold and 
defined it as the commonly accepted threshold.
3.6  Cost‑Effectiveness of Original Results and Key 
Drivers of Cost‑Effectiveness
3.6.1  Ezetimibe
Five out of eight studies (62.5%) [32, 33, 35, 42, 43] from 
a healthcare perspective and Soini et al. [36] from a soci-
etal perspective considered ezetimibe to be cost effec-
tive compared with statins. In addition, Davies et al. [13] 
considered ezetimibe to be cost effective from a US payer 
perspective assuming a 90% price reduction due to patent 
expiration. Of the five studies set in the US, three studies 
(60%) reported an ICER below the WTP threshold, from 
a healthcare [42, 43] or a payer’s perspective [13]. The 
original results from the two earliest studies by Kazi et al. 
[12, 44] reported ezetimibe to be above the US$100,000/
QALY threshold commonly used. Of note, one study was an 
update [44], so differences between studies were minimal. 
The most recent study by Kazi et al. [43], using the same 
model but published after patent expiration, reported the 
ICER of ezetimibe to be below the mentioned threshold. 
Finally, the study by Kongpakwattana et al. [45] did not 
consider ezetimibe to be cost effective from a healthcare 
or societal perspective according to the WTP threshold in 
Thailand. The results for total health outcomes and total 
costs are summarised in Table 2.
All the studies reported increased health benefits with the 
addition of ezetimibe to statins versus statin monotherapy, 
with incremental QALYs ranging from 0.10 in Kongpakwat-
tana et al. [45] to 0.62 in the oldest study by Kazi et al. [12]. 
Interestingly, in the three studies by Kazi et al. [12, 43, 44], 
the health benefits (incremental QALYs) were lower in the 
most recent study [43] compared with previous ones [12, 
44], but the ICER is also lower, reflecting the price reduction 
of the drug after patent expiration. Detailed information on 
health benefits, original costs, and adapted costs are sum-
marised in Table 2.
Three studies did not report sensitivity analyses for 
ezetimibe [33, 35, 44] while the remaining seven studies [12, 
13, 32, 36, 42, 43, 45] had undertaken both deterministic and 
probabilistic sensitivity analyses. Additionally, four studies 
[12, 42, 43, 45] reported scenario and threshold analyses and 
three studies [13, 36, 43] also included sub-group analyses.
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There was a variety of drivers of cost-effectiveness. Cost 
of ezetimibe was identified by three studies [12, 13, 43] 
and time horizon by another three [12, 32, 42]. Non-fatal 
coronary heart disease rates were identified as an impor-
tant parameter by Davies et al. [13], and Kongpakwattana 
et al. [45] identified the treatment effect on mortality as the 
essential parameters for cost-effectiveness. Additionally, 
Soini et al. [36] reported the results of sub-group analysis, 
showing that changes in baseline LDL-C levels, gender and 
diabetes status had no significant influence in the model. 
Although Reckless et al. [35] did not report results from 
sensitivity analysis, the authors mentioned the risk coronary 
heart disease as the main driver for cost-effectiveness, with 
highest risk rates giving lower ICERs.
3.6.2  PCSK9 Inhibitors
From the healthcare system perspective, one out of ten stud-
ies (10%) [39] considered PCSK9 inhibitors to be cost effec-
tive compared with statins. Additionally, Gandra et al. [26] 
and Fonarow et al. [38] considered PCSK9 inhibitors to be 
cost effective versus statins, from a US payer and a societal 
perspective. From the eight studies set in the US [12, 26, 29, 
37, 38, 43, 44, 48], two studies (25%) considered PCSK9 
inhibitors to be cost effective, one from a payer [26] per-
spective, and one from a societal perspective [38]. Of note, 
the ICERs of PCSK9 inhibitors versus statins were gener-
ally lower than when compared with statins plus ezetimibe. 
Health benefits, total costs, and adapted costs are summa-
rised in Table 2.
In all the studies [12, 26, 28, 30, 33, 37–39, 43–48], the 
cost-effective analysis of PCSK9 inhibitors for patients with 
a history of CVD and LDL-C levels > 70 mg/dL yielded 
additional QALYs per person, ranging between 0.17 [45] 
and 1.12 [26].
Eight studies [12, 26, 37, 39, 43, 45, 46, 57] performed 
deterministic sensitivity analyses, and nine studies [12, 26, 
33, 37, 39, 43, 45, 46, 57] also conducted probabilistic sen-
sitivity analyses.
The cost of PCSK9 inhibitors was identified as the main 
driver of cost-effectiveness in five of the included studies 
[12, 43, 46–48]. Three studies [26, 37, 39] considered the 
effect of the reduction of plasma LDL-C on cardiovascular 
risk as the most influential parameter and Kongpakwattana 
et al. [45] reported treatment effect on mortality risks to be 
the key drivers of cost-effectiveness. Time horizon was men-
tioned in one study [12], with longer time horizons produc-
ing better ICERs. Three studies [30, 44, 57] did not explore 
key influences in their analysis. Interestingly, in one study 
by Fonarow et al. [37], the authors used the same model 
with two different sources for the baseline risks, US claims 
data and data from the FOURIER trial. Results showed that 
the ICERs obtained with data from FOURIER were much 
higher, and thus less cost effective than those obtained with 
US claims.
3.6.3  n‑3 PUFA
Out of the five studies, all from a healthcare perspective, 
three (60%) [40, 49, 50] considered the addition of n-3 
PUFAs to statin therapy to be a cost-effective strategy versus 
statin monotherapy, while the other two studies, Permpanich 
et al. [31] and Gao et al. [51], did not consider the interven-
tion to be cost effective. None of the studies analysing n-3 
PUFAs were set in the US. The five studies reported a gain 
in health benefits from the intake of n-3 PUFAs ranging from 
0.08 additional QALYs per person in Cowie et al. [40] to 
2.01 QALYS per person in Permpanich et al. [31]. Total and 
adapted costs and health benefits are summarised in Table 2.
All the studies performed deterministic and proba-
bilistic sensitivity analyses [31, 40, 49–51], two studies 
reported scenario and threshold analyses [49, 50] and Gao 
et al. [51] reported results for the expected value of perfect 
information.
Time horizon was an important driver in four of the stud-
ies [40, 49–51], the cost of n-3 PUFAs was identified in three 
studies [31, 50, 51] and population mortality rates due to 
CVD were also identified in three studies [49–51]. In addi-
tion, discounting rates were described as influential in two 
of the studies [31, 51] but were not influential in two other 
studies [40, 50]. In scenario analyses, the study by Kodera 
et al. [49] noted that the results were no longer cost effective 
when compared with high-potency statin treatment instead 
of low to medium potency. The study by Permpanich et al. 
[31] highlighted that the ICER decreased as age increased, 
making it a more cost-effective strategy for older patients. 
In addition, Ademi et al. [50] showed that the intervention 
was no longer cost effective if age-related population trends 
were not applied into the model.
3.6.4  Polypill
All the studies adopting a healthcare perspective considered 
the polypill to be cost effective [34, 41, 53, 55] or cost saving 
[54] compared with multiple monotherapies. Additionally, 
Gaziano et al. [27] reported the polypill to be cost saving 
from a societal perspective. From the two studies [27, 52] set 
in the US, one study (50%) considered the polypill to be cost 
saving from a healthcare perspective [27], while the other 
did not consider it cost effective from a societal perspective 
[52]. Total costs, total health benefits and adjusted costs are 
summarised in Table 2.
All the studies reported a small increase in health benefits 
with the polypill compared with multiple monotherapies, 
with gained QALYs per person ranging from 0.02 [52] to 
0.05 [54].
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All the studies [27, 34, 41, 52–55] reported deterministic 
and probabilistic sensitivity analyses and five out of seven 
studies [34, 41, 53–55] also performed scenario analyses.
Three studies [41, 54, 55] reported utility values as the 
most influential parameter for cost-effectiveness [41, 54, 55], 
followed by adherence rates to polypill [27, 34, 41], and rates 
of cardiovascular events, particularly myocardial infarction. 
In addition, Gaziano et al. [27] reported the polypill cost as 
a determinant of cost-effectiveness.
3.7  Adaptation of Cost‑Effectiveness Studies 
to 2018 US Dollars
Four out of six studies (66%) [35, 42, 43, 45] that evalu-
ated ezetimibe from a healthcare perspective had ICERs 
below US$100,000 after adapting costs to 2018 US dollars 
(Fig. 2). The value of the ICERs ranged from US$27,195 
in Kongpakwattana et al. [45] to US$204,140 in Kazi et al. 
2017 [44] in studies adopting a healthcare perspective. The 
results from the two studies adopting a societal perspective 
[36, 45] ranged from US$149,136 for women in the study 
by Soini et al. [36] to US$27,361 in Kongpakwattana et al. 
[45].
After adapting costs to 2018 US dollars, none of the 
PCSK9 inhibitor studies adopting a healthcare perspective 
had ICERs below US$100,000 (Fig. 2). There was an impor-
tant variation in the values of the ICERs for PCSK9 inhibi-
tors, from US$231,119 in Villa et al. [39] to US$1,223,831 
in the study by Kongpakwattana et al. [45], in both cases 
from a healthcare perspective. From a societal perspective, 
ICERs ranged from US$56,655 in the most recent study by 
Fonarow et al. [38] incorporating new pricing and diagnosis 
guidelines, to US$1,223,995 in the study by Kongpakwat-
tana et al. [45].
Three out of four studies (75%) [40, 50, 51] analysing n-3 
PUFAs had ICERs below US$100,000 after cost adaptation 
(Fig. 2). The adapted ICERs for n-3 PUFAs versus statin 
therapy had a smaller range, from US$57,128 in the oldest 
Fig. 2  Cost-effectiveness plane, displaying costs adapted to 2018 US 
dollars and original effect estimates for studies adopting a healthcare 
perspective. All studies used a lifetime horizon, except for Barrios 
et  al. [53] and Becerra et  al. [52]. Circles represent data after cost 
adjustment, and triangles non-adjusted data (originally reported in 
2018 USD). EZT ezetimibe, QALY quality-adjusted life years
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study [40] to US$139,082 in the study by Kodera et al. [49], 
all being from a healthcare perspective.
For the polypill, three out of the four studies (75%) [41, 
54, 55] adjusted to 2018 US dollars had ICER values below 
US$100,000 (Fig. 2).The polypill had important variations 
as well in the results from the adapted ICERs, ranging from 
being dominant (i.e. cost saving) in Barrios et al. [54] to 
US$133,000 in the oldest study by Ito et al. [52].
The results of the studies using a healthcare perspective 
and adjusted to 2018 US dollars are included in a common 
cost-effectiveness plane (Fig. 2). Cost-effectiveness planes 
for studies using a societal perspective are available in 
Appendix 3 (see ESM).
4  Discussion
In general, ezetimibe, n-3 PUFAs and the polypill are cost 
effective compared with standard therapy (statin monother-
apy for ezetimibe and n-3 PUFAs and multiple monothera-
pies for the polypill), while most studies analysing PCSK9 
inhibitors considered them not cost effective when compared 
with statins or statins plus ezetimibe.
Our results revealed that seven out of the ten included 
studies [12, 13, 32, 33, 35, 36, 42] considered ezetimibe plus 
statins to be cost effective or reported an ICER below the 
usual WTP threshold for their setting when compared with 
statin monotherapy, in patients with established CVD and 
LDL-C levels > 70 mg/dL despite statin treatment. These 
results are in accord with a previous systematic review by 
Suh et al. [58], who indicated that ezetimibe was cost effec-
tive for patients intolerant to statins, with chronic kidney 
disease or not reaching plasma LDL-C therapeutic levels. 
For ezetimibe, the main cost-effectiveness drivers were cost 
of the drug [12, 13], baseline cardiovascular risks [35, 42] 
and treatment effect related to cardiovascular and non-car-
diovascular mortality [13, 45]. These parameters were also 
identified as crucial drivers for cost-effectiveness in a recent 
systematic review analysing pharmacological treatments for 
heart failure [59].
Twelve out of 15 studies [12, 28–30, 33, 37, 43–48] indi-
cated that PCSK9 inhibitors were not cost effective with 
current pricing and WTP thresholds compared with statin 
monotherapy or statins plus ezetimibe for patients with 
established CVD. The reported ICERs were significantly 
higher when compared with ezetimibe plus statins. Similar 
results have been published in previous systematic reviews 
[58, 60], although these reviews were not specific for sec-
ondary prevention. Drug cost was the main driver of cost-
effectiveness in five studies [12, 43, 44, 47, 48]. Most of the 
studies that used LDL-C levels to extrapolate cardiovascular 
risk identified this parameter as one of the main drivers of 
cost-effectiveness.
The analysis of cost-effectiveness studies on n-3 PUFAs 
showed that three out of five studies [40, 49, 50] considered 
the addition of n-3 PUFAs to statins to be cost effective 
when compared with statin monotherapy. Similar results 
were reported by Sadler et al. [61], although their results 
were not specific to secondary prevention. The time horizon 
was the main driver of cost-effectiveness for n-3 PUFA. The 
relatively small health benefits of the intervention versus 
standard therapy make time horizon a pivotal element, since 
the cost will only be offset in the long term.
The cost-effectiveness results of the polypill showed 
that it was cost saving/cost effective compared with mul-
tiple monotherapies for secondary prevention populations. 
Although there is no other specific review on the cost-effec-
tiveness of fixed-dose combinations for patients with estab-
lished CVD, other systematic reviews of interventions that 
aimed to increase adherence [62] have shown similar results, 
and it was shown to be cost effective for primary prevention 
in LMICs [22, 63]. Interestingly, two of the analysed stud-
ies [34, 41] mentioned the need for synergistic approaches 
to improve adherence to guideline-based prescription and 
treatment together with the polypill.
4.1  Limitations of the Present Systematic Review
Our review has several limitations. The generalisation of the 
cost-effectiveness results is debatable, since most of the clini-
cal effectiveness data emanates from Western countries, with 
only a small percentage of clinical data coming from studies 
undertaken in Asia, and none in Africa or South America. 
Moreover, most of the studies are set in high-income coun-
tries, which determines the costs of long-term treatment and 
prescriptions and reflects the need for more studies using data 
from LMICs [63]. In addition, the differences between the 
healthcare systems in different countries and the discrepan-
cies in WTP thresholds also make generalisation difficult. 
The exclusion of non-peer-reviewed publications, such as 
publications by health technology assessment bodies, means 
that we may have missed some important models.
The structural variation among the studies can also 
increase the uncertainty of the overall conclusions, as seen 
for primary prevention in hypertensive patients [64]. The 
lack of publicly available models limits the capacity to com-
pare between settings and countries, since many model fea-
tures remain obscure [65].
The estimates derived from the adaptation of cost results 
cannot be directly interpreted as ICERs for the US, only as 
an approximation of cost-effectiveness levels to be expected 
for the US. Nevertheless, the overall cost-effectiveness 
results in the four analysed strategies were consistent when 
adapted to the US setting. Of note, original consideration of 
cost-effectiveness from LMIC was less likely to be consist-
ent after adaptation to the US setting.
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4.2  Limitations of the Reviewed Cost‑Effectiveness 
Studies
The cost-effectiveness studies analysed also had some limi-
tations. Lower adherence rates have been shown to lead to 
worse health outcomes and increased costs for healthcare 
systems [66]; however, adherence was only modelled in six 
out of seven studies evaluating the cost-effectiveness of the 
polypill [27, 34, 41, 52, 54, 55] and in none of the studies 
analysing other interventions in this systematic review. In 
many cases, assumptions were made about utility values to 
derive QALYs gained due to lack of evidence.
Health technology agencies recommend the use of clini-
cal endpoints instead of surrogate markers [67]. The use of 
surrogate markers (i.e. lipid levels to estimate the relative 
risk reduction in cardiovascular events), in most cases due 
to lack of clinical trials describing hard outcomes, increased 
the uncertainty of the models. Some studies showed that 
LDL-C poses a cumulative risk and that decreases in LDL-C 
levels will not necessarily mean an immediate decrease in 
cardiovascular risk [68]. Most of the studies did not explore 
the effect of starting the treatment at different age ranges, 
which can have a significant influence given the focus on 
populations with established CVD. In addition, some mod-
els used data from the statin arm of clinical trials to model 
baseline risk of cardiovascular events while others used local 
demographic data. The use of clinical trials to model event 
rates could lead to an underestimation of the baseline risk 
and the treatment effect [69]. In our study, we were not able 
to observe any clear trend on whether the use of clinical 
trials data generated improved cost-effectiveness results 
compared with using observational studies with regards to 
baseline risk and treatment effect.
Only Ademi et  al. [50], Gaziano et  al. [27] and Lin 
et al. [34] considered adverse events and subsequent costs, 
although another four studies [12, 32, 43, 44] incorporated 
adverse events as a decrement utility or as an extra cost. The 
majority of the cost-effectiveness studies undertook a health-
care perspective, highlighting the gap in evidence and the 
need for analysing results from a societal perspective. While 
most patients included in these studies were beyond typi-
cal working age, since the mean age for almost all studies 
was > 60 years, out-of-pocket payments and caregiver time 
should have been considered, which would likely improve 
the cost-effectiveness.
5  Conclusions
Ezetimibe and n-3 PUFAs represent cost-effective strategies 
for the secondary prevention of CVD compared with statin 
monotherapy. Similarly, the polypill is cost saving or cost 
effective compared with multiple monotherapies. PCSK9 
inhibitors did not meet cost-effectiveness thresholds in most 
of the studies reviewed. Time horizon and cardiovascular 
risks were the main drivers for n-3 PUFAs and the cardio-
vascular polypill. Drug cost, time horizons and cardiovascu-
lar risks were the main drivers for ezetimibe and the ICERs 
for PCSK9 inhibitors were mainly influenced by the cost of 
the drugs and the relative reduction of cardiovascular risk.
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